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ARTICLE
Conformational dynamics of the human serotonin
transporter during substrate and drug binding
Ingvar R. Möller 1,2, Marika Slivacka1,2, Anne Kathrine Nielsen 2, Søren G.F. Rasmussen3, Ulrik Gether 3,
Claus J. Loland 2 & Kasper D. Rand 1
The serotonin transporter (SERT), a member of the neurotransmitter:sodium symporter
family, is responsible for termination of serotonergic signaling by re-uptake of serotonin (5-
HT) into the presynaptic neuron. Its key role in synaptic transmission makes it a major drug
target, e.g. for the treatment of depression, anxiety and post-traumatic stress. Here, we apply
hydrogen-deuterium exchange mass spectrometry to probe the conformational dynamics of
human SERT in the absence and presence of known substrates and targeted drugs. Our
results reveal signiﬁcant changes in dynamics in regions TM1, EL3, EL4, and TM12 upon
binding co-transported ions (Na+/K+) and ligand-mediated changes in TM1, EL3 and EL4
upon binding 5-HT, the drugs S-citalopram, cocaine and ibogaine. Our results provide a
comprehensive direct view of the conformational response of SERT upon binding both bio-
logically relevant substrate/ions and ligands of pharmaceutical interest, thus advancing our
understanding of the structure-function relationship in SERT.
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Serotonin (5-HT) as a neurotransmitter is involved in manybasal brain functions such as mood, sleep, and appetite. Theintensity of 5-HT transmission is tightly regulated by fast
removal of released 5-HT by the serotonin transporter (SERT),
which is embedded in the presynaptic membrane. The transport
by SERT is a Na+-coupled secondary active process, meaning that
it harnesses the energy in the Na+-gradient across cell mem-
branes, to drive the transport of 5-HT against its concentration
gradient. For every molecule 5-HT, one Na+ and one Cl− ion is
co-transported1,2. A concomitant counter transport of K+ ren-
ders the transport process electroneutral3.
The overarching importance of 5-HT in basal physiological
functions makes SERT a natural drug target in the treatment of
multiple mental diseases. Accordingly, the selective serotonin
reuptake inhibitors (SSRIs), such as S-citalopram, sertraline, and
paroxetine, are currently in use for the treatment of, e.g.,
depression, anxiety, obsessive–compulsive disorders, and post-
traumatic stress disorder. The tricyclic antidepressants, e.g., imi-
pramine and amitriptyline also target SERT. In addition, SERT
inhibition contributes to the action of psychotropic and illicit
drugs such as MDMA (ecstasy), ibogaine, cocaine, and
amphetamine4.
SERT is a member of the neurotransmitter:sodium symporter
(NSS) family that also includes the transporters for the
neurotransmitters dopamine, norepinephrine, glycine, and γ-
aminobutyric acid. The family moreover encompasses multiple
other transporters for amino acids and metabolites5. The non-
polar amino acid transporter, LeuT, from Aquifex aeolicus was
the ﬁrst NSS member for which a crystal structure was solved6.
The structure revealed a protein with 12 transmembrane (TM)
spanning domains with a pseudo twofold symmetry between
TM1–5 and 6–10, now known as the LeuT-fold. A binding site
(S1 site) for the substrate leucine was found to be located to the
center of the protein ﬂanked by TM1, 3, 6, and 8. Two sodium
ions were bound in the structure; one (Na1 site) in direct contact
with the bound leucine and the other (Na2 site) in close
proximity6.
NSS proteins are thought to function by an alternating access
mechanism by which the central binding site is alternatingly
accessible to either the extracellular or intracellular environment.
Accordingly, the transporter exists in a dynamic equilibrium
between different conformations, which can be biased toward a
speciﬁc conformation by the binding of ions, substrates, or spe-
ciﬁc inhibitors. X-ray structures have been solved of LeuT in three
distinct conformations supporting the alternating access
mechanism: a Na+-bound outward open, a Na+ and leucine-
bound outward occluded, and an inward open apo-form6,7. While
providing detailed structural insight, these structures represent
static “snapshots” of a dynamic protein.
Structural dynamics of NSS proteins have been investigated
extensively in LeuT with several biophysical methods such as
electron spin resonance8,9, ﬂuorescent- and ﬂuorescence
resonance energy transfer (FRET) spectroscopy studies10–14
and hydrogen–deuterium exchange (HDX) mass spectrometry
(MS)15,16. They show that the binding of Na+ and leucine pro-
motes an opening of the outer gate, destabilizing the extracellular
domains and increases their solvent accessibility toward the
binding site8–14,16. Conversely, the intracellular domains are
stabilized by this action. We have previously used HDX-MS on
LeuT to make the intriguing observation that the binding of
solutes promotes slow cooperative structural ﬂuctuations of the
intracellular part of TM1, 5, and 7 as well as within the binding
site region of TM615. An helical unwinding of TM5 has also been
observed in other bacterial members of the NSS family17. It has
been proposed that the function is a priming of LeuT for sub-
sequent intracellular release of Na+ and substrate through the
release of an N-terminal interaction18. A role of K+ has been
shown for SERT function, that is K+ binds to the inward-facing
transporter and is transported out of the cell, rendering the
transport charge-neutral19 and speeding up the return-step of
the transport cycle20. Interestingly, recent ﬁndings suggest a role
of K+ also in LeuT. For this transporter, it was found that K+
inhibits Na+ and substrate binding, and biases the transporter
toward an inward facing conformation, thereby stabilizing the
extracellular domains and destabilizing the intracellular face13,15.
The solved structures of both hSERT21 and dDAT22 have
shown an overall fold very similar to LeuT, suggesting a structural
and mechanistic conservation within the NSS family of proteins.
The hSERT crystal structure revealed an outward-open con-
formation with S-citalopram or paroxetine bound in the S1 site.
The binding sites for two Na+ and a Cl− ion are also found in the
structure. All three ions are located similar to the positions found
in dDAT21,22. In addition to the central binding site, an addi-
tional S-citalopram molecule is bound within an extracellular
vestibule (the S2 site), a cone-shaped water-ﬁlled cavity which
provides the entry pathway for the S1-bound molecule as well as
Na+ and Cl−, conﬁrming previous ﬁndings23. However, in spite
of the apparent structural similarity between LeuT and SERT, and
several MD simulations of SERT24–26, our knowledge from
experimental data on the conformational dynamics of SERT is
incomplete and based on indirect inferences from biochemical
and electrophysiological studies27–31 often using SERT mutants.
A greater insight into these aspects would be of utmost impor-
tance for a better understanding of 5-HT homeostasis and how
this can be affected by current and future medications.
HDX-MS provides an attractive method to study the con-
formational dynamics of membrane proteins32–34 and has been
used to study transporters including the effect of substrates on
LeuT15,16, the effect of interactions between phospholipids and
well-characterized model transporters from E. coli35, and the
effect of consensus mutagenesis for thermostabilization of the
human glutamate transporter36. By this technique, the exchange
of hydrogen to deuterium of backbone amides in a protein is
measured by use of MS. Amide HDX is primarily determined by
the presence and strength of local hydrogen bonding. Changes in
the rate of HDX is, thus, closely correlated to conformational
properties and dynamics of a protein37,38. An advantage with
HDX-MS is it allows for probing the conformational dynamics of
the entire protein backbone in a non-perturbing manner and
readily facilitates comparative analyses between different protein
conditions39–42.
Here, we apply HDX-MS to probe the conformational
dynamics of hSERT induced by the addition of ions (Na+ or K+),
substrate (5-HT) or inhibitors (S-citalopram, cocaine, and ibo-
gaine). By measuring changes in deuterium uptake as a function
of ion- and ligand-bound states, we map ligand-induced differ-
ences in structural stabilities within speciﬁc hSERT domains. We
ﬁnd that K+ and Na+ bound states show signiﬁcantly different
HDX in regions which have been implicated in the transition
from outward to inward facing conformations but also in regions
with hitherto unknown roles. The binding of known substrate (5-
HT) and drug ligands (S-citalopram, cocaine, and ibogaine) has
diverse conformational impacts on hSERT, primarily observed
through their effect on segments spanning TM1a and EL3, thus
providing molecular insights into the substrate transport
mechanism and the binding of drugs.
Results
Puriﬁcation of human SERT. To enable HDX-MS experiments,
hSERT was expressed in Expi293F cells using the BacMam pro-
cedure43. The cells were harvested and lysed by sonication. The
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membranes were collected by centrifugation and solubilized in a
buffer containing 20 mM dodecyl maltoside (DDM). DDM-
solubilized hSERT was puriﬁed by afﬁnity chromatography and
eluted into a stabilizing buffer containing DDM (1 mM) and a
mixture of lipids (POPC:POPE:POPG; 1:1:1 ratio). Sodium
dodecyl sulphate polyacrylamide gel electrophoresis analysis of
the puriﬁcation indicated around 20–25% purity and the
absence of SERT proteolysis products in the hSERT sample used
for HDX-MS was conﬁrmed by western blotting analysis (Sup-
plementary Fig. 1). The activity of puriﬁed DDM-solubilized
hSERT was veriﬁed by a saturation binding assay using [3H]
imipramine (Supplementary Fig. 1). The Kd was measured to
be 7.5 ± 0.7 nM (mean ± SE, n= 3), which correlated with pre-
vious reports1,44. Additional analyses of the purity and veriﬁca-
tion of stability of puriﬁed hSERT can be found in Supplementary
Figs. 1 and 2.
Conformational dynamics of hSERT in solution. Extensive
HDX-MS optimization using on-line rhizopuspepsin digestion45
allowed the identiﬁcation of 62 peptides covering 69.1% of the
protein sequence that were used to measure the HDX of local
regions of hSERT across all states examined (Supplementary
Results and Supplementary Fig. 3 for further details).
According to the crystal structure21, the 12 TM helices make up
approximately 52% of hSERT protein sequence and at least 12%
form helical structural motifs in loops and terminal areas. Helices
are primarily stabilized by hydrogen bond networks and the HDX
of these regions would be expected to be reduced compared to
that of unstructured parts of the transporter. We thus used the
HDX of hSERT measured at the earliest time point (0.25min) in a
Na+ -containing buffer to detect the presence of hydrogen-bonded
structure elements of hSERT in solution (Fig. 1)38. As Na+ is
required for transport, Na+ was used as the reference state for
investigating the conformation of hSERT and furthermore
investigating the relative conformational impact of ligands.
In most instances, the deuterium uptake of regions shown to
comprise TMs in the crystal structure followed a pattern of
having slow HDX corresponding to the formation of TMs in the
solution phase. However, parts of TM2, TM3, TM6, and TM10,
displayed faster HDX than expected, resulting in over 40% of the
backbone amides already being labeled with deuterium after
0.25 min, compared to a maximum labeled control sample. In the
case of TM2, the peptides included both the TM region and an
unstructured segment where the latter could explain the observed
elevated HDX. However, the extracellular part of TM3 (peptide
number 26), intracellular parts of TM6 (peptide number 37), and
the extracellular part of TM10 (peptide number 47) did not
include unstructured segments. The ﬂexibility could make them
particularly responsive to conformational transitions.
We note that the observed ﬂexibility of parts of TM3, TM6,
and TM10 could be due to local structural perturbations caused
by the nonnative solubilization conditions employed (DDM
detergent micelle). However, the observed full binding activity of
detergent-solubilized SERT used for HDX-MS makes this
unlikely and furthermore the X-ray crystal structure of SERT
reveals these helices to be partially solvated, which provide an
alternate explanation for their elevated HDX To address whether
HDX in some SERT domains could be inﬂuenced by partly
unfolding, we performed HDX-MS experiments on puriﬁed SERT
batches after sample pretreatment steps that involved storage at
room temperature for 1 h. All samples yielded similar HDX
proﬁles (Supplementary Fig. 2). Such locally resolved measure-
ments are very sensitive to detect even modest local changes in
SERT conformation due to partial unfolding or aggregation
during the time-frame of the HDX experiment.
The impact of K+ on the conformational dynamics of hSERT.
Unlike any other mammalian NSS family member, the transport
cycle of hSERT has been reported to possess a counter-transport
of K+4. To investigate the effect of K+ on hSERT conformation,
we performed HDX of hSERT in a K+-containing buffer and
compared to hSERT in Na+-containing buffer (reference state,
Figs. 1 and 2).
K+ induced signiﬁcant changes in HDX (and hence conforma-
tional dynamics) in multiple regions of hSERT relative to the
Na+-bound state (Fig. 2). Decreased HDX was observed in a
segment spanning the upper part of TM6a (residues 319–329)
and segments within the two helices and interconnecting loop in
EL4 (residues 397–406). Increased HDX was observed on the
intracellular face in residues located in the N-terminus (residues
70–83), TM1a (residues 84–95), EL3 (residues 296–305 and
312–320), along with the intracellular parts of TM12b (residues
595–598). Together, these data are consistent with a stabilization
or closing of this continuous extracellular region of hSERT and a
coordinated destabilization or opening of the intracellular
segments when converting to a K+-containing buffer.
The presence of K+ also induced unusually slow
unfolding–refolding kinetics (EX1 kinetics) in TM1b (residues
99–109). Proteins commonly undergo HDX according to a
regime where the breakage and formation of amide H-bonds is
uncorrelated and faster than the rate of HDX, which is
characterized by a single binomial isotopic distribution that
gradually migrates to higher mass-to-charge (m/z) with increased
deuteration of the protein (EX2 kinetics). EX2 kinetics was
observed in all regions of hSERT across all states, apart from
TM1b in the K+-bound state. EX1 kinetics reﬂects slow
cooperative structural ﬂuctuations where the reformation of H-
bonds is slower than the rate of HDX. This causes a correlated
exchange of the backbone amide hydrogens allowing HDX-MS to
detect two protein populations present in solution: an already-
exchanged population and a yet-to-exchange population. As the
two populations have not incorporated the same amount of
deuterium, their mass differs, and they can be distinguished from
each other by mass analysis. For TM1b (residues 99–109), the two
populations differed in HDX by six deuteriums (Supplementary
Fig. 4), indicating that in the presence of K+, at least six backbone
amide hydrogens—corresponding to almost two helical turns—
undergo correlated exchange in this part of hSERT. It suggests
that the dynamics of the extracellular side of TM1 is considerably
slowed by the presence of K+. TM1b forms part of the
extracellular gate and is known to be involved in substrate
transport. By extension, our results suggest that the opening and
closing motions of the extracellular gate is signiﬁcantly modulated
and slowed by the binding of K+ relative to the Na+-bound
SERT.
In control experiments, the impact on the dynamics of hSERT
by imidazole from the puriﬁcation buffer was evaluated by
measuring the HDX of hSERT in the presence and absence of
imidazole, both in Na+ and K+ buffers. No substantial differences
in HDX were observed for hSERT with and without imidazole in
Na+ buffer. Intriguingly, some HDX differences were observed
for hSERT in K+ buffer. Segments covering TM1b (residues
99–109), part of TM5 along with EL3 (residues spanning from
296 to 320), TM10 and TM12 with the C-terminally located helix
showed increased HDX in the presence of imidazole (Supple-
mentary Fig. 5). Notably, all subsequent ligand-binding experi-
ments were performed in Na+ buffer.
5-HT binding induces distinct conformational dynamics.
hSERT is responsible for the reuptake of the 5-HT from the
synaptic cleft. To probe the conformational dynamics induced by
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Fig. 1 Conformational dynamics of hSERT in solution. a The relative deuterium uptake of representative peptides is plotted as a function of labelling time
(0.25–480min) when hSERT was in the presence of Na+ (blue), K+ (orange), and Na+ with 5-HT (red). Error bars indicate standard deviations for the
0.25, 10, and 60min time points (n= 2–4). Maximum labelled controls are indicated with a black dot. Peptides showing a difference in deuterium uptake
between at least two states are coloured cyan on the crystal structure (PDB: 5i75). Orange indicates that EX1 kinetics was observed for at least one
experimental state. Black solid lines at the top and bottom of the structural model show an approximation of the extracellular (Ex.) and intracellular (Int.)
boundaries of the membrane, respectively. b The HDX of hSERT measured at the earliest time point (0.25min) in the presence of Na+, normalized to the
maximum labelled control sample, and plotted as a function of peptide number (Supplementary Table 1). Structural elements are indicated along the x-axis
above the plot. (*) marks peptides where information was not available. Source data for the HDX data are provided as a Source data ﬁle
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5-HT binding, we measured the HDX of hSERT in the
presence of 5-HT (10 µM) and compared it to the Na+-bound
state (Figs. 1 and 3).
5-HT induced signiﬁcant changes in the dynamics of the
protein resulting in HDX distinguishable from that observed
when the transporter was in the presence of either K+ or Na+
(Fig. 3). Similar to K+, 5-HT binding increased HDX in the N-
terminal tail immediately prior to TM1a (residues 70–83). This
domain includes a conserved arginine residue (Arg79), which has
been proposed to form a salt bridge to Asp452 in IL47,46. Its
breakage likely mediates the transition towards the inward facing
state. The ﬁrst ﬁve residues of the TM1a helix itself (residues
84–89) were also destabilized. Increased HDX was also observed
in EL3 (segments covered by peptides 306–311 and 312–320)
analogue to the K+-bound state. A decreased HDX was
observed for the remainder of the TM1 segment (residues
spanning 89–95+ 99–109). These changes in stabilization is
probably a signature for a transition toward the inward facing
C
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Fig. 2 Comparison of the HDX of hSERT in the presence of Na+ and K+. a A difference plot illustrating the difference in HDX between the Na+ and K+
states for the 62 peptides identiﬁed from hSERT over the measured time points (orange—0.25 min; red—1 min; cyan—10min; green—1 h; black—8 h).
Positive and negative values indicate decreased or increased HDX, respectively, when hSERT is in the presence of K+ compared to Na+. The peptides are
arranged according to their position from the N- to C-terminal (Supplementary Table 1). A dotted line is plotted at ±0.34D, indicating the 95% CI as a
threshold for signiﬁcance. Structural motifs in hSERT are indicated along the x-axis above the plot as well as the occurrence of EX1 kinetics. b, c Regions
showing signiﬁcant increase (red) or decrease (blue) in dynamics (i.e., HDX) in the presence of K+ compared to Na+ are plotted on the crystal structure
(PDB ID: 5i75) (b) and a snake diagram (c) of hSERT. Regions coloured grey indicates insigniﬁcant difference in HDX between the two experimental states
(light grey) or regions not covered by peptides (dark grey). Regions showing signiﬁcant difference in HDX are indicated with black text with residue
location in the structural model. Structural elements located on the front side of the crystal structure but do not show signiﬁcant difference in HDX are
indicated with grey text without residue information for orientation. Regions not resolved or truncated in the crystal structure are indicated with dotted
lines. Black solid lines at the top and bottom of the structural model show an approximation of the extracellular (Ex.) and intracellular (Int.) boundaries of
the membrane, respectively. Source data for the HDX data are provided as a Source data ﬁle
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state. We also observed signiﬁcant differences between 5-HT and
K+ bound states, particularly in EL4 and the C-terminal part of
TM12. It could suggest that the changes are induced by Na
+-binding and not further modulated by substrate. The data
presented here clearly suggest a difference in the substrate-bound
conformations of LeuT and hSERT, whereas LeuT is further
stabilized in its Na+-bound state by leucine10,15, 5-HT binding to
hSERT both stabilizes but also destabilizes regions relative to the
Na+-bound form. hSERT has been proposed to favor an inward-
facing conformation in the presence of 5-HT47, and the structural
stabilization observed in TM1b by 5-HT may be indicative of a
closing of the extracellular gate. Our HDX data, however, does
not support a complete transition to an inward-facing state
similar to suggestions in previously reported MD simulations25.
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Structural stabilization upon binding of S-citalopram.
S-citalopram is a widely used antidepressant, which inhibits
transport of 5-HT by SERT through competitive inhibition48. To
evaluate the effect of S-citalopram on the conformational
dynamics of hSERT and detect regions directly or indirectly
affected by ligand binding, the HDX of the transporter was per-
formed in the presence of S-citalopram and compared to its Na+-
bound state.
The binding of S-citalopram led to signiﬁcant structural
stabilization in TM1 (Fig. 4a, d). Decreased HDX was observed
in the region immediately preceding TM1 as well as throughout
the TM1 domain (residues 70–95 and 99–109, residues 96–98
were not covered by any peptides). According to the crystal
structure, TM1a participates in the binding of S-citalopram
through Tyr95 which forms a π–π interaction with its amine
group and possibly through a hydrogen bond with its oxygen21.
However, residues not reported to participate directly in S-
citalopram binding, such as the N-terminal tail (residues 70–94)
also underwent stabilization. This could possibly be due to
allosteric restraints brought on by the inhibitor binding such as
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the stabilization of the conserved salt bridge between Arg79 and
Asp452. In our previous HDX-MS study on LeuT, the outward-
facing state of LeuT in the presence of Na+ showed structural
destabilization in TM1b15 which is opposite to what is observed
for hSERT, here in the presence of S-citalopram. TM1b is known
to be important in transporting substrate, making up a part of the
extracellular gate, participating in coordination of Na1 as well as
containing a salt bridge between Arg104 and Glu49321. Its
structural stabilization could be caused by S-citalopram restrict-
ing the movement of TM1b and possibly preventing hSERT from
isomerizing into the outward-facing occluded conformation.
Binding of cocaine leads to stabilization of TM1a. Cocaine is a
substance of abuse which primarily exerts its stimulant effects
through DAT inhibition49 and increasing the synaptic con-
centration of dopamine50. However, cocaine's nonselective nature
also causes it to inhibit transport of 5-HT through competitive
inhibition of hSERT51. To gain insight into the hSERT binding
conformation induced by cocaine, we performed HDX on hSERT
in the presence of 2.4 µM cocaine and compared the effects to the
Na+-bound state.
Relative to the Na+-bound state, the addition of cocaine led to
stabilization of TM1a (residues 84–95) and the region immedi-
ately before the TM1 helix (residues 70–83) (Fig. 4b, e). As for S-
citalopram, cocaine binding is reported to promote an outward-
facing conformation of hSERT47 through an interaction with
Tyr9552, perhaps causing a stabilization of the salt bridge between
Arg79 and Asp452 on the intracellular side. However, the lack of
sequence coverage in TM8-IL4-TM9 eludes the identiﬁcation of a
possible corresponding stabilization in IL4. Unlike S-citalopram,
the binding of cocaine to hSERT did not have a signiﬁcant impact
on the dynamics of TM1b (residues 99–109), indicating that the
hSERT binding dynamics between the two compounds is
different.
Similar conformational response in hSERT to ibogaine and K+.
The phychedelic alkaloid ibogaine from the African shrub
Tabernanthe iboga has been suggested as a possible treatment for
drug addiction53. It is also an inhibitor of SERT although less
potent than S-citalopram and cocaine. It has been proposed that
ibogaine inhibits 5-HT transport through a noncompetitive
action and possibly inducing an inward-open SERT conforma-
tion54,55. If this is correct, it would likely result in a HDX pattern
which is markedly different from our observations for S-
citalopram and cocaine. Accordingly, we performed HDX-MS
on puriﬁed hSERT in the presence of ibogaine.
Relative to the buffer with Na+ only, the addition of ibogaine
led to a structural destabilization of the region immediately before
TM1a as well as TM1a itself (residues 70–95) along with a
segment spanning EL3 (residues 312–320). Oppositely, stabiliza-
tion was observed in segments spanning TM1b (residues 99–109)
and parts of EL4a and EL4b (residues 397–406) (Fig. 4c, f). The
observed effects in TM1 are literally opposite to our observations
for cocaine and S-citalopram but similar to the effects on hSERT
in K+-containing buffer. Based on HDX-MS on LeuT, we have
previously proposed that the stabilization of TM1b and EL4 and
the destabilization of TM1a were connected with the transition
towards an inward-facing conformation15. Here, the destabiliza-
tion of TM1a and stabilization of TM1b by ibogaine could
indicate an initiation towards a similar transition. Also the
stabilization of EL4 supports this suggestion as the tip of EL4 in
LeuT has been shown by X-ray crystallography to act as a lid for
the closure of the extracellular vestibule in LeuT7.
Discussion
The structural models of NSS proteins, from bacteria to hSERT
have been of utmost importance in studying the protein structure
and possible mechanism of NSS proteins6,7,17. However, trunca-
tions, mutations, or deletions have been required for the crys-
tallization of the eukaryotic NSS proteins, sometimes even
rendering them incapable of transport. In other complementary
studies, techniques such as electron spin resonance8,9, ﬂuores-
cence-10 and FRET-based11–13 strategies have been applied, but
they also require modiﬁcations to the protein to conjugate the
reporter probes. A major advantage of HDX-MS is that it can be
performed on an intact and unmodiﬁed protein, still capable of
assuming all possible functional states. We have recently reported
the HDX-MS study of LeuT wild type in the presence and absence
of substrate/ions, providing insights into the solution-phase
conformational dynamics of this prokaryotic transporter15.
However, it is currently unknown to what extent our knowledge
of the conformational dynamics and substrate/ion-induced
changes in LeuT reﬂect those occurring in human neuro-
transmitter transporters.
Here, we provide insights into the solution-phase conforma-
tional dynamics of puriﬁed hSERT in the presence of Na+, K+, 5-
HT, and selected inhibitors. In the presence of K+, structural
destabilization was observed in hSERT immediately prior to
TM1a, TM1a itself, and EL3 while TM1b and EL4 became sta-
bilized. We have previously reported similar structural destabili-
zation in LeuT, showing that the two transporters share
similarities in their response to K+. Compelling data suggest that
K+ is counter-transported relative to the inward transport of Na+
and 5-HT56, which could support a bias toward a more inward-
facing structure by K+. The impact of K+ on hSERT revealed in
this study clearly support this hypothesis and maps which regions
are involved in this transition (peptides spanning residues 70–89,
89–95, 99–109, 296–305, 312–329, 397–406, and 400–406). LeuT
was also shown to favor an inward-facing conformation in the
Fig. 4 Comparison of the HDX of hSERT in the presence and absence of drug inhibitors. Difference plots illustrating the difference in HDX between the Na+
and inhibitor states (a S-citalopram; b cocaine; c ibogaine) for the 62 peptides identiﬁed from hSERT over the measured time points (orange—0.25min; red
—1 min; cyan—10 min; green—1 h; black—8 h). Positive and negative values indicate decreased or increased HDX, respectively, when hSERT is in the
presence of each respective inhibitor with Na+ compared to Na+ only. The peptides are arranged according to their position from the N- to C-terminal
(Supplementary Tables 2 and 3). A dotted line is plotted at ±0.43 (a) and ± 0.45 D (b, c), indicating the 95% CI as a threshold for signiﬁcance. Structural
motifs in hSERT are indicated along the x-axis above or below each the plot. d–f Regions showing signiﬁcant increase (red) or decrease (blue) in dynamics
(i.e., HDX) in the presence of inhibitor (d S-citalopram, e cocaine, f ibogaine) with Na+ compared to Na+ alone are plotted on the crystal structure of
hSERT (PDB ID: 5i75). Regions coloured grey indicates insigniﬁcant difference in HDX between experimental states or regions not covered by peptides.
Regions showing signiﬁcant difference in HDX are indicated with black text with residue location in the structural model. Structural elements located on the
front side of the crystal structure but do not show signiﬁcant difference in HDX, are indicated with grey text without residue information for orientation and
regions not resolved or truncated in the crystal structure are indicated with dotted lines. Black solid lines at the top and bottom of the structural model
show an approximation of the extracellular (Ex.) and intracellular (Int.) boundaries of the membrane, respectively. Source data for the HDX data are
provided as a Source data ﬁle
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presence of K+13. LeuT also showed signiﬁcant differences in
TM6 where no differences were seen in hSERT (Fig. 2), sug-
gesting that K+ binding also impacts the two transporters dif-
ferently. Lack of sequence coverage in TM5 and TM7 of hSERT
prevented comparison of these two regions with our previous
analysis of LeuT.
An intriguing difference could be seen in the type of kinetics
observed in the two transporters. EX1 kinetics were observed in
numerous regions of LeuT (parts of TM1a, TM5, TM6, TM7,
EL2, and EL4b), but were only visible in TM1b of K+-bound
hSERT. Based on the high structural similarities between hSERT
and LeuT, it is unlikely that their mechanism of transport is
dramatically different. The lack of widespread EX1 kinetics in
hSERT (and thus inherently faster refolding dynamics) could
correlate nicely with reported difference in the rate of substrate
turnover (kcat (LeuT)= ~0.0003 s−157; kcat (hSERT)= 1–3 s−158).
We observed a similar HDX pattern in hSERT in the presence
of K+ and 5-HT (with Na+), with destabilization in a segment
preceding and including the beginning of TM1a (residues 70–88,
Fig. 1a) and a stabilization of TM1b (Fig. 5), suggesting that both
ligands induced similar conformational features. However, we
saw differences in TM1a and the extracellular loop regions (EL3
and EL4) between binding K+ and 5-HT, revealing also differ-
ences in the conformations induced by these two ligands (Figs. 2,
3, and 5). These differences may be caused by K+ promoting an
inward-facing open conformation, while 5-HT may still be
occupying the binding pocket (observed by reduced HDX for
residues 89–95) in either a partial inward-facing open or closed
conformation. Similar results have been obtained with unbiased
MD simulations of SERT in complex with Na+ and 5-HT59. They
found that 5-HT binding leads to an isomerization of SERT to an
inward-facing state, largely mediated by conformational changes
in TM1a and 6b. Also in accordance with the present results, they
propose that the two-halves of these helices are internally ﬂexible
with the intracellular part of the helices moving considerably
more than the extracellular part.
hSERT in the presence of S-citalopram is reported to favor an
outward-facing conformation60, ﬁtting with the crystal structure
of the transporter21. Relative to the Na+-bound state, we observe
that S-citalopram binding only causes signiﬁcant stabilization in a
segment encompassing TM1 and a region preceding this helix
(Figs. 4a, d and 5). According to the hSERT crystal structure21
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and several MD simulations24,60–62, S-citalopram is suggested to
interact with both Tyr95 and Asp98 in TM1 but also with other
SERT regions, including TM3 (Ile172 and Tyr176), TM6 (Phe335,
Ser336, and Phe341), TM8 (Ser438 and Thr439), and TM10
(Thr497 and Val501). These regions (excluding Ser438, 439, and
Val501, which were not possible to probe here) did not show a
signiﬁcant difference in HDX. Using the patch clamp technique
on HEK cells expressing SERT, it has been suggested that the
transporter already adopts an outward-facing open conformation
merely by the presence of Na+20. The increased structural sta-
bility observed throughout TM1 is then caused by S-citalopram
interacting with Tyr95 and Asp98 as well as its bulky structure
signiﬁcantly hampering the structural ﬂuctuations of the entire
TM1 of hSERT. Similarly, the cocaine binding site could be
formed by Na+. This is supported by MD simulations showing
that cocaine stabilized an outward-facing conformation, both in
SERT25 and DAT49. Thus, the observed stabilization by both
inhibitors (Fig. 4) in TM1a, which includes Arg79 that forms a
conserved salt bridge to Asp452 (Fig. 5), and the region imme-
diately preceding it (residues 70–95) is likely to be important for
trapping the transporter in an outward-facing conformation.
Nevertheless, a stabilization of TM1b was not observed in
hSERT by the binding of cocaine. The difference in stabilization
between the two inhibitors may be due to cocaine being less bulky
than S-citalopram, allowing for more movement of TM1b.
Experiments were in both cases performed at approximately 90%
binding occupancy, thus the differences in afﬁnity of the two
ligands was taken into account as much as possible (see Methods
section for further details). An alternative explanation is that S-
citalopram, even at this relatively low concentration (340 nM),
also associates to the S2 site causing a further stabilization of the
molecule. However, the S2 site would be expected to only be
occupied in around 6.5% of hSERT (IC50= 4.6 ± 0.4 µM23) pre-
sent during HDX labeling. Also, we would expect S2 binding to
cause a substantial stabilization of large stretches in multiple TM
domains, which we do not observe here.
Out of the three inhibitors tested here, hSERT is only reported
to favor an inward-facing conformation in the presence of ibo-
gaine55. Like in the presence of K+, ibogaine-induced structural
destabilization was observed in TM1a and EL3 while TM1b and
EL4 were stabilized. Though the conformational dynamics of
hSERT in the presence of K+ and ibogaine are similar, differences
could be seen including the exchange kinetics in TM1b. Thus,
with ibogaine, the TM1b region exchanges according to EX2
kinetics but in the presence of K+ according to EX1 kinetics.
Ibogaine binding has been reported to be non-competitive to 5-
HT54 and the lack of stabilization in the middle of TM1a (resi-
dues 89–95) seen with 5-HT but not for ibogaine, supports the
hypothesis that ibogaine does not share a binding site with 5-HT.
All three ligands (i.e., K+, 5-HT, and ibogaine) caused struc-
tural destabilization of the region preceding TM1a, TM1a itself
and stabilization of TM1b, indicating this to be a signature of an
inward-facing conformation in hSERT (Fig. 5). Other signiﬁcant
differences in the stability of hSERT varied between the three
states. In particular, 5-HT still causes stabilization of TM1a
(residues 89–95, (Fig. 5)). This could suggest that the transition
from outward-to-inward has yet to be completed. MD simula-
tions have supported this suggestion by elegantly showing that
the solvent accessible surface area on the SERT intracellular side
was higher in the noribogaine-bound transporter relative to 5-HT
bound25. Another possibility is that our measurements are per-
formed on hSERT in detergent and accordingly does not allow
imposing a Na+ gradient. This suggestion is supported by the
stabilizing effect on EL4 by K+ and ibogaine, but not 5-HT. In
LeuT, EL4 plays an important role in closing access from the
extracellular side7. If 5-HT binding only promotes but does not
complete the transition to the inward-facing conformation, the
stabilization of EL4 might not be evident without the presence of
a gradient.
Taken together, here we use HDX-MS to provide an unper-
turbed global view of the conformational dynamics of wild-type
human SERT in solution and how such dynamics are modulated
by binding of endogenous substrate (5-HT), co-transported ions
(Na+/K+) and drug ligands (S-citalopram, cocaine, and ibo-
gaine). Our results show that several loops and TM helices of the
transporter undergo distinct changes in dynamics upon binding
the substrate 5-HT and K+ relative to the Na+-bound state.
Substrate-bound hSERT exhibits a clear difference in HDX rela-
tive to our previous observations on LeuT in the presence of
leucine15. Thus, hSERT differs from LeuT in its conformational
bias upon substrate binding, depicting limitations in using LeuT
as a model protein for eukaryotic NSS proteins. By spatially
resolving regions that change conformation in different func-
tional and drug-bound states of hSERT, our results provide a
framework for an improved understanding of the alternating
access mechanism that governs the function of human SERT and
could open up for novel drug strategies. Our ﬁndings should be
impactful in reﬁning our understanding of the conformational
dynamics of hSERT and present/future structural models of
distinct conformational states of hSERT (e.g., X-ray generated or
based on computational models) will be supported by, and should
account for, the experimental measurements on conformational
dynamics of hSERT reported here. Considering that the transport
mechanism and drug binding for SERT is dictated by its higher-
order structure, we envisage that our results could be pertinent to
other human transporters bearing the conserved NSS fold as these
may operate via a similar mechanism of action.
Methods
Recombinant hSERT construct. Full-length hSERT with a C-terminal thrombin
site (LVPRGS) followed by a 12 histidine-tag was synthesized and cloned into the
pEG BacMam expression vector43 by Genscript Inc. (Piscataway, NJ). Further
information on the recombinant hSERT construct can be found in the Supple-
mentary Information.
Expression and puriﬁcation of human serotonin transporter. Baculovirus for
the expression of hSERT was produced using Sf9 cells (Expression Systems). The
virus was used for the infection of mammalian Expi293F cells (Gibco)43. The
Expi293F cells were incubated at 37 °C, 5% CO2, 70% humidity, 130 rpm, in
Expi293 Expression Medium (Gibco) until they reached density optimized for the
expression of hSERT (here, 1.2–1.5 × 106 cells/ml culture). The cells were infected
with 1% of P1 virus that was added along with 2 mM of valproic acid, and the cells
incubated for two days at 37 °C, 5% CO2, 70% humidity, 130 rpm, before har-
vesting. The cells were harvested at 6200g, frozen and stored at −80 °C. The cells
were gently thawed and resuspended in cold lysis buffer (20 mM Tris (pH 8.0),
150 mM NaCl, 100 µM tri(2-carboxyethyl)phosphine (TCEP), 0.5 mM cholesteryl
hemisuccinate (CHS), 30% glycerol, and protease inhibitors benzamidine and
leupeptin, both in 10 µg/ml) and ruptured by sonication (Branson Soniﬁer 250 set
at 50% duty cycle and output control 5). Non-lysed cells were removed by cen-
trifugation (750g) for 15 min at 4 °C. Cell membranes were collected by cen-
trifugation of the supernatant at 125,000g for 2 h. The membranes were
subsequently resuspended in solubilization buffer (20 mM Tris (pH 8.0), 150 mM
NaCl, 500 µM TCEP, 4 mM CHS, 20 mM N-dodecyl-β-D-maltoside (DDM), 5 µg/
ml benzamidine and 10 µg/ml leupeptin). The solubilized protein was puriﬁed by
batch puriﬁcation with single step nickel afﬁnity puriﬁcation and eluted with
20 mM Tris (pH 8.0), 300 mM NaCl, 500 µM TCEP, 300 mM imidazole, 0.5 mM
CHS, 24 µM of lipid mixture (POPC:POPE:POPG; 1:1:1 ratio), 1 mM DDM, 5%
glycerol, 5 µg/ml benzamidine, and 10 µg/ml leupeptin. The detergent and lipids
added during SERT puriﬁcation have been previously reported along with the
structure of hSERT by Coleman et al.21.
Scintillation proximity assay for veriﬁcation of activity. The activity of hSERT
was veriﬁed by saturation binding using scintillation proximity assay (SPA) per-
formed largely as described previously10. hSERT at a ﬁnal concentration of 0.4 µg/
ml was added to a solution of YSi-Cu2+ SPA beads (125 µg/ml, Perkin Elmer), and
[3H]imipramine in sample buffer (20 mM Tris (pH 8.0), 300 mM NaCl, 500 µM
TCEP, 0.5 mM CHS, 24 µM of lipid mixture (POPC:POPE:POPG; 1:1:1 ratio),
1 mM DDM, 5% glycerol) was added in a concentration range (1–48 nM),
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performed in triplicates. Unspeciﬁc binding (10 µM paroxetine) was determined in
parallel. The binding experiment was incubated at room temperature for 30 min
followed by overnight incubation at 4 °C to obtain equilibrium conditions. Binding
activity was quantiﬁed on a MicroBeta scintillation counter (PerkinElmer). Fol-
lowing subtraction of the counts caused by non-speciﬁc binding, the data was
plotted in GraphPad Prism version 6 and ﬁtted to a one site saturation binding
curve, allowing for the extraction of the Kd.
Hydrogen/deuterium exchange. Prior to HDX labeling, puriﬁed hSERT was
dialyzed or diluted 1:4 (in the case of the HDX-MS experiments with inhibitors)
into sample buffer (26 mM Tris (pH 8.0), 500 µM TCEP, 0.5 mM CHS, 24 µM of
lipid mixture (POPC:POPE:POPG; 1:1:1 ratio), 1 mM DDM, 5% glycerol) con-
taining either 300 mM NaCl or 300 mM KCl resulting in a ﬁnal concentration of
2.16 µM. For HDX of hSERT in the presence of ligands, individual ligands were
added as a part of the NaCl-containing sample buffer. 5-HT or inhibitors were
added in a concentration that yielded a 90% binding occupancy of hSERT (0.31
µM) during the deuterium labeling reactions, based on published afﬁnities (ligand
concentrations: 10, 0.34, 2.4, and 25.5 µM, for 5-HT (Kd: ~1 µM)44,63, S-citalopram
(Kd: ~5 nM)4,44,64, cocaine (Kd: ~220 nM)4,44, and ibogaine (Kd: ~2.6 µM)55,65,
respectively). The HDX reactions were initiated by diluting the hSERT equilibra-
tion solutions 1:6.5 with deuterated buffer (26 mM Tris (pH 8.0), 500 µM TCEP,
0.5 mM CHS, 24 µM of lipid mixture (POPC:POPE:POPG; 1:1:1 ratio), 1 mM
DDM with either 300 mM of NaCl or 300 mM of KCl), resulting in 85% deuterium
content during HDX. HDX reactions were incubated for speciﬁc time periods
(0.25, 1, 10 minutes, 60, and 480 min) at 25 °C before a sample was extracted from
the reaction tube and quenched by 1:1 dilution into ice cold quench buffer (219
mM potassium phosphate (pH 2.5), 6 M urea, 1 mM DDM). Quenched samples
were immediately frozen at −80 °C and stored until their intended measurements
by liquid chromatography mass spectrometry (LC–MS).
We note that the HDX-MS ligand-binding experiments were performed using
ligand concentrations which should ensure ~90% binding occupancy of hSERT,
excluding effects caused by differences in afﬁnity by any of the ligands. However, as
the transporter was around 20–25% pure during HDX-MS (Supplementary Fig. 1),
variability could occur in the binding occupancy of hSERT if the ligands displayed
different unspeciﬁc binding to protein impurities present. Such a scenario would
impact the exact magnitude of HDX differences observed, thus while our results
reveal which regions of hSERT are perturbed by different ligands, a detailed
quantitative comparison of HDX differences between different ligands should be
approached with caution. Further, though puriﬁed from a non-neuronal cell line,
some hSERT interacting proteins could remain in the sample. These possible
interaction partners would however be present in all states (including the reference
state) and any impact on hSERT should thus be the same in all HDX experiments.
Additionally, in a control experiment where the HDX of the Na+-bound reference
state was performed following size exclusion chromatography (SEC), and thus
under conditions with signiﬁcantly fewer impurities, hSERT showed identical
HDX, within the experimental error, to afﬁnity-puriﬁed hSERT (Supplementary
Fig. 2).
Liquid chromatography and mass spectrometry. Frozen quenched samples were
quickly thawed in a table top centrifuge and injected into a refrigerated (0 °C)
UPLC platform (NanoAcquity, Waters). The protein was passed through a self-
pack column containing rhizopuspepsin immobilized on POROS 20AL resin at 20 °
C. The generated peptides were trapped on a Vanguard column (C8, 130 Å, 1.7 µm,
2.1 mm × 5mm; Waters) and desalted for 4 min at a ﬂow rate of 150 µl/min solvent
A (0.23% formic acid in MQ water, pH 2.5). Subsequently, the peptides were
separated over an Acquity UPLC column (C8, 130 Å, 1.7 µm, 1 mm × 100 mm;
Waters) with a linear gradient rising from 8 to 30% solvent B (0.23% formic acid in
acetonitrile). Following the chromatographic separation, the peptides were ana-
lyzed using a hybrid ESI-Q-TOF mass spectrometer (Synapt G2-Si, Waters). The
MS was set in positive ionization mode and the peptides were further separated by
ion mobility for enhanced peak capacity. For peptide identiﬁcation, nondeuterated
samples were injected and subjected to identical chromatographic separation. The
peptides were fragmented by collision-induced dissociation using argon as collision
gas, either in data dependent (DDA) or data independent acquisition (DIA) mode.
Maximum-labeled control samples. Maximum-labeled controls were prepared by
loading samples of hSERT on the same UPLC platform described above. However,
following on-line rhizopuspepsin digestion, the peptides were trapped on a Van-
guard trap column, desalted, eluted and manually collected. The mobile phase was
evaporated using a SpeedVac (ThermoFisher). The pre-digested samples were
resuspended in 85% deuterium buffer and incubated overnight before the samples
were quenched as described for other HDX samples.
Evaluation of stability. Puriﬁed hSERT (50 µg in 300 µl) was injected onto an
ÄKTA FPLC system with a Superose 6 Increase 10/300 GL. The separation was
performed at 0.5 ml/min using sample buffer (20 mM Tris (pH 8.0), 300 mM NaCl,
500 µM TCEP, 0.5 mM CHS, 24 µM of lipid mixture (POPC:POPE:POPG; 1:1:1
ratio), 1 mM DDM, 5% glycerol) as a mobile phase. Fractions were collected from
4ml until the end of the analysis. Fractions corresponding to hSERT were
upconcentrated from 2.5 ml to approximately 100 µl for HDX-MS analysis. For the
evaluation of stability by HDX-MS, SEC-puriﬁed SERT was prepared with or
without 1 h pre-incubation at 25 °C. The HDX labeling was performed over
selected time intervals (0.25, 10, and 60 min) using HDX sample buffer containing
300 mM NaCl, and analyzed by LC-MS as described for other HDX-MS samples.
Butterﬂy plots were prepared for comparison of individual states according to the
following equation:
NormalizedHDX ¼ HDXsample
HDXMXcontrol
; ð1Þ
where HDXsample is the deuterium uptake of a peptide at a respective measurement
time point and HDXMX control is the experimentally determined maximum deu-
terium content of the peptide. Normalized deuterium uptake for two states was
presented as either positive or negative values for each peptide. Negative values
were calculated by multiplying the deuterium content of peptides with “−1” to
obtain a mirror image for comparison.
HDX-MS data analysis. MS/MS data was processed with ProteinLynx Global
Server (PLGS) version 3.0 (Waters), for peptide identiﬁcation. Peptides identiﬁed
by DDA had to have PLGS Ladder Score above 1.0, below 15 ppm mass error for
the precursor ion, along with passing manual inspection of the fragment spectrum
in PLGS. DynamX version 3.0 (Waters) was used to ﬁlter peptides identiﬁed by
DIA with the peptides having to be fragmented at least 3 times, 0.1 fragmentations
per amino acid, and below 10 ppm mass error for the precursor ion. Further, the
peptides had to be identiﬁed in 2:3 of the acquired MS/MS ﬁles. Lastly, the presence
of a signal for the precursor ion was veriﬁed in DynamX along with analysis of
deuterium uptake of all positively identiﬁed peptides. Maximum labeled controls
were used to calculate the back exchange (BE) for individual peptides by the
following equation:
BE ð%Þ ¼ 1mmax m0%
NDfrac
 
´ 100%; ð2Þ
where mmax is the mass of a maximum labeled peptide, m0% is the mass of a
nondeuterated peptide, and Dfrac is the fraction of deuterium in the HDX labeling
buffer and N is the number of peptide amide hydrogens. Calculated BE values were
used to support the identiﬁcation of hSERT peptides and to validate HDX-MS
system performance. The plotted deuterium uptake proﬁles were not corrected
for BE.
Preliminary HDX-MS screening experiments (n= 1) were performed on
hSERT states with all time points (0.25, 1, 10, 60, 480 min). Based on the
preliminary experiments, the ﬁnal HDX-MS data set was obtained from a series of
comprehensive HDX-MS experiments performed on fresh batches of hSERT (n= 3
biological replicates) with technical replicate measurements obtained for selected
time points (n= 2–4 technical replicates).
To determine whether a difference in HDX between two states was signiﬁcant
or not, the standard deviation of time points performed at least in triplicate was
used to calculate a conﬁdence interval. The standard deviation of individual
peptides (n= 3) was averaged across the states being compared. The average
standard deviation was then used to calculate the accumulated standard deviation
and the 95% conﬁdence interval (CI)
σave ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
n ´ σ2
p
; ð3Þ
CI ¼ x ± t ´ σaveﬃﬃﬃ
n
p ; ð4Þ
where σave is the accumulated average standard deviation, x ̅ is the assumed zero-
centered average difference in HDX between two states (i.e., x ̅= 0), t is the table
value for the two-tail 95% CI with two degrees of freedom (t95%, n=3= 4.303), σa̅ve
is the averaged standard deviation for all measured peptides, and n is the number
of replicates (n= 3). In the comparative HDX analysis of the different functional
states, a peptide was only considered to have a signiﬁcant difference in HDX if two
consecutive time points showed a signiﬁcant difference in deuterium incorporation
above the average CI or based on a Student's t-test (p < 0.01). As an exemption to
this rule, a difference was also considered signiﬁcant if the last time point (480 min)
displayed a difference in HDX at least two times larger than the CI, as this indicates
a signiﬁcantly expanding difference not fully sampled by the HDX time course.
To allow access to the HDX data of this study, the HDX Data Tables
(Supplementary Tables 1–3) and the HDX Data Summary Table (Supplementary
Table 4) are included in the Supporting Information according to the community-
based recommendations66.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Data supporting the ﬁndings of this manuscript are available from the corresponding
authors upon reasonable request. A reporting summary for this Article is available as a
Supplementary Information ﬁle. The source data underlying Figs. 1, 2, 3, 4, 5c, and
Supplementary Figs. 1, 2, 5, 6, 7, 8, are provided as a Source Data ﬁle. Mass spectrometry
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data ﬁles including processed DynamX ﬁles and an overview of the HDX-MS data
(Supporting Tables 1–4) have been uploaded to the PRoteomics IDEntﬁcation (PRIDE)
Database.
Received: 17 July 2018 Accepted: 22 March 2019
References
1. Talvenheimo, J., Fishkes, H., Nelson, P. J. & Rudnick, G. The serotonin
transporter-imipramine ‘receptor’. J. Biol. Chem. 258, 6115–6119 (1983).
2. Nelson, P. J. & Rudnick, G. The role of chloride ion in platelet serotonin
transport. J. Biol. Chem. 257, 6151–6155 (1982).
3. Keyes, S. R. & Rudnick, G. Coupling of transmembrane proton gradients to
platelet serotonin transport. J. Biol. Chem. 257, 1172–1176 (1982).
4. Kristensen, A. S. et al. SLC6 neurotransmitter transporters: structure, function,
and regulation. Pharma. Rev. 63, 585–640 (2011).
5. Saier, M. H. TCDB: the Transporter Classiﬁcation Database for membrane
transport protein analyses and information. Nucleic Acids Res. 34, D181–D186
(2006).
6. Yamashita, A., Singh, S. K., Kawate, T., Jin, Y. & Gouaux, E. Crystal structure
of a bacterial homologue of Na+/Cl–dependent neurotransmitter
transporters. Nature 437, 215–223 (2005).
7. Krishnamurthy, H. & Gouaux, E. X-ray structures of LeuT in substrate-free
outward-open and apo inward-open states. Nature 481, 469–474 (2012).
8. Claxton, D. P. et al. Ion/substrate-dependent conformational dynamics of a
bacterial homolog of neurotransmitter:sodium symporters. Nat. Struct. Mol.
Biol. 17, 822–829 (2010).
9. Kazmier, K. et al. Conformational dynamics of ligand-dependent alternating
access in LeuT. Nat. Struct. Mol. Biol. 21, 472–479 (2014).
10. Billesbølle, C. B. et al. Substrate-induced unlocking of the inner gate
determines the catalytic efﬁciency of a neurotransmitter: Sodium symporter. J.
Biol. Chem. 290, 26725–26738 (2015).
11. Zhao, Y. et al. Single-molecule dynamics of gating in a neurotransmitter
transporter homologue. Nature 465, 188–193 (2010).
12. Zhao, Y. et al. Substrate-modulated gating dynamics in a Na+-coupled
neurotransmitter transporter homologue. Nature 474, 109–113 (2011).
13. Billesbølle, C. B. et al. Transition metal ion FRET uncovers K+ regulation of a
neurotransmitter/sodium symporter. Nat. Commun. 7, 12755 (2016).
14. Tavoulari, S. et al. Two Na+ sites control conformational change in a
neurotransmitter transporter homolog. J. Biol. Chem. 291, 1456–1471 (2016).
15. Merkle, P. S. et al. Substrate-modulated unwinding of transmembrane helices
in the NSS transporter LeuT. Sci. Adv. 4, eaar6179 (2018).
16. Adhikary, S. et al. Conformational dynamics of a neurotransmitter:sodium
symporter in a lipid bilayer. Proc. Natl Acad. Sci. 114, E1786–E1795 (2017).
17. Malinauskaite, L. et al. A mechanism for intracellular release of Na+ by
neurotransmitter/sodium symporters. Nat. Struct. Mol. Biol. 21, 1006–1012
(2014).
18. Stolzenberg, S. et al. The role of transmembrane segment 5 (TM5) in Na2
release and the conformational transition of neurotransmitter:sodium
symporters toward the inward-open state. J. Biol. Chem. 292, 7372–7384
(2017).
19. Nelson, P. J. & Rudnick, G. Coupling between platelet 5-hydroxytryptamine
and potassium transport. J. Biol. Chem. 254, 10084–10089 (1979).
20. Schicker, K. et al. Unifying concept of serotonin transporter-associated
currents. J. Biol. Chem. 287, 438–445 (2012).
21. Coleman, J. A., Green, E. M. & Gouaux, E. X-ray structures and mechanism of
the human serotonin transporter. Nature 532, 334–339 (2016).
22. Penmatsa, A., Wang, K. H. & Gouaux, E. X-ray structure of dopamine
transporter elucidates antidepressant mechanism. Nature 503, 85–90 (2013).
23. Plenge, P. et al. Steric hindrance mutagenesis in the conserved extracellular
vestibule impedes allosteric binding of antidepressants to the serotonin
transporter. J. Biol. Chem. 287, 39316–39326 (2012).
24. Koldsø, H. et al. The two enantiomers of citalopram bind to the human
serotonin transporter in reversed orientations. J. Am. Chem. Soc. 132,
1311–1322 (2010).
25. Koldsø, H., Autzen, H. E., Grouleff, J. & Schiøtt, B. Ligand induced
conformational changes of the human serotonin transporter revealed by
molecular dynamics simulations. PLoS One 8, 1–13 (2013).
26. Grouleff, J., Ladefoged, L. K., Koldsø, H. & Schiøtt, B. Monoamine
transporters: insights from molecular dynamics simulations. Front.
Pharmacol. 6, 1–15 (2015).
27. Fenollar-Ferrer, C. et al. Structure and regulatory interactions of the
cytoplasmic terminal domains of serotonin transporter. Biochemistry 53,
5444–5460 (2014).
28. Sørensen, L. et al. Interaction of antidepressants with the serotonin and
norepinephrine transporters. J. Biol. Chem. 287, 43694–43707 (2012).
29. Zhang, Y.-W., Turk, B. E. & Rudnick, G. Control of serotonin transporter
phosphorylation by conformational state. Proc. Natl Acad. Sci. 113,
E2776–E2783 (2016).
30. Felts, B. et al. The two Na+ sites in the human serotonin transporter play
distinct roles in the ion coupling and electrogenicity of transport. J. Biol.
Chem. 289, 1825–1840 (2014).
31. Hasenhuetl, P. S., Freissmuth, M. & Sandtner, W. Electrogenic binding of
intracellular cations deﬁnes a kinetic decision point in the transport cycle of
the human serotonin transporter. J. Biol. Chem. 291, 25864–25876 (2016).
32. Hvidt, A. & Linderstrøm Lang, K. Exchange of hydrogen atoms in insulin with
deuterium atoms in aqueous solutions. Biochim. Biophys. Acta 14, 574–575
(1954).
33. Hvidt, A. & Nielsen, S. O. Hydrogen exchange in proteins. Adv. Protein Chem.
21, 287–386 (1966).
34. Englander, S. W. & Krishna, M. M. G. Hydrogen exchange. Nat. Struct. Biol. 8,
741–742 (2001).
35. Martens, C. et al. Direct protein-lipid interactions shape the conformational
landscape of secondary transporters. Nat. Commun. 9, 4151 (2018).
36. Cirri, E. et al. Consensus designs and thermal stability determinants of a
human glutamate transporter. eLife 7, 1–22 (2018).
37. Skinner, J. J., Lim, W. K., Bédard, S., Black, B. E. & Englander, S. W. Protein
dynamics viewed by hydrogen exchange. Protein Sci. 21, 996–1005 (2012).
38. Skinner, J. J., Lim, W. K., Bédard, S., Black, B. E. & Englander, S. W. Protein
hydrogen exchange: testing current models. Protein Sci. 21, 987–995 (2012).
39. Morgan, C. R. & Engen, J. R. Investigating solution-phase protein structure
and dynamics by hydrogen exchange mass spectrometry. Curr. Protoc. Protein
Sci. 1–17 (2009) (Chapter 17, Unit 17.6).
40. Chalmers, M. J., Busby, S. A., Pascal, B. D., West, G. M. & Grifﬁn, P. R.
Differential hydrogen/deuterium exchange mass spectrometry analysis of
protein-ligand interactions. Expert. Rev. Proteomics 8, 43–59 (2011).
41. Konermann, L., Pan, J. & Liu, Y.-H. Hydrogen exchange mass spectrometry
for studying protein structure and dynamics. Chem. Soc. Rev. 40, 1224–1234
(2011).
42. Jensen, P. F. & Rand, K. D. Hydrogen exchange: a sensitive analytical window
into protein conformation and dynamics. in Hydrogen Exchange Mass
Spectrometry of Proteins: Fundamentals, Methods, and Applications (ed. Weis,
D. D.) 1–17 (John Wiley & Sons, Chichester, West sussex, PO19 8sQ, United
Kingdom, 2016).
43. Goehring, A. et al. Screening and large-scale expression of membrane proteins
in mammalian cells for structural studies. Nat. Protoc. 9, 2574–2585 (2014).
44. Rasmussen, S. G. F. & Gether, U. Puriﬁcation and ﬂuorescent labeling of the
human serotonin transporter. Biochemistry 44, 3494–3505 (2005).
45. Rey, M., Man, P., Brandolin, G., Forest, E. & Pelosi, L. Recombinant
immobilized rhizopuspepsin as a new tool for protein digestion in hydrogen/
deuterium exchange mass spectrometry. Rapid Commun. Mass Spectrom. 23,
3431–3438 (2009).
46. Loland, C. J., Grånäs, C., Javitch, J. A. & Gether, U. Identiﬁcation of
intracellular residues in the dopamine transporter critical for regulation of
transporter conformation and cocaine binding. J. Biol. Chem. 279, 3228–3238
(2004).
47. Zhang, Y. W. & Rudnick, G. The cytoplasmic substrate permeation pathway of
serotonin transporter. J. Biol. Chem. 281, 36213–36220 (2006).
48. D’Amato, J. R., Largent, L., Snyder, H. & Johns, T. Selective labeling of
serotonin uptake sites in rat brain by contrasted to labeling of multiple sites by
[3H]citalopram contrasted to labeling of multiple sites by [3H]imipramine. J.
Pharmacol. Exp. Ther. 242, 364–371 (1987).
49. Beuming, T. et al. The binding sites for cocaine and dopamine in the
dopamine transporter overlap. Nat. Neurosci. 11, 780–789 (2008).
50. Chen, R. et al. Abolished cocaine reward in mice with a cocaine-insensitive
dopamine transporter. Proc. Natl Acad. Sci. 103, 9333–9338 (2006).
51. Ritz, M. C., Cone, E. J. & Kuhar, M. J. Cocaine inhibition of ligand binding at
dopamine, norepinephrine and serotonin transporters: a structure-activity
study. Life. Sci. 46, 635–645 (1990).
52. Wang, K. H., Penmatsa, A. & Gouaux, E. Neurotransmitter and
psychostimulant recognition by the dopamine transporter. Nature 521,
322–327 (2015).
53. Noller, G. E., Frampton, C. M. & Yazar-Klosinski, B. Ibogaine treatment
outcomes for opioid dependence from a twelve-month follow-up
observational study. Am. J. Drug Alcohol. Abuse 44, 37–46 (2018).
54. Bulling, S. et al. The mechanistic basis for noncompetitive ibogaine inhibition
of serotonin and dopamine transporters. J. Biol. Chem. 287, 18524–18534
(2012).
55. Jacobs, M. T., Zhang, Y. W., Campbell, S. D. & Rudnick, G. Ibogaine, a
noncompetitive inhibitor of serotonin transport, acts by stabilizing the
cytoplasm-facing state of the transporter. J. Biol. Chem. 282, 29441–29447
(2007).
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09675-z
12 NATURE COMMUNICATIONS |         (2019) 10:1687 | https://doi.org/10.1038/s41467-019-09675-z | www.nature.com/naturecommunications
56. Rudnick, G. Bioenergetics of neurotransmitter transport. J. Bioenerg.
Biomembr. 30, 173–185 (1998).
57. Singh, S. K., Yamashita, A. & Gouaux, E. Antidepressant binding site in a bacterial
homologue of neurotransmitter transporters. Nature 448, 952–956 (2007).
58. Quick, M. W. Regulating the conducting states of a mammalian serotonin
transporter. Neuron 40, 537–549 (2003).
59. Koldsø, H. et al. Unbiased simulations reveal the inward-facing conformation
of the human serotonin transporter and Na+ ion release. PLoS Comput. Biol.
7, e1002246 (2011).
60. Andersen, J. et al. Mutational mapping and modeling of the binding site for
(S)-citalopram in the human serotonin transporter. J. Biol. Chem. 285,
2051–2063 (2010).
61. Andersen, J. et al. Location of the antidepressant binding site in the serotonin
transporter: Importance of Ser-438 in recognition of citalopram and tricyclic
antidepressants. J. Biol. Chem. 284, 10276–10284 (2009).
62. Sørensen, L. et al. Interaction of antidepressants with the serotonin and
norepinephrine transporters: Mutational studies of the S1 substrate binding
pocket. J. Biol. Chem. 287, 43694–43707 (2012).
63. Bröer, S. & Gether, U. The solute carrier 6 family of transporters. Br. J.
Pharmacol. 167, 256–278 (2012).
64. Owens, M. J., Knight, D. L. & Nemeroff, C. B. Second-generation SSRIs:
human monoamine transporter binding proﬁle of escitalopram and R-
ﬂuoxetine. Biol. Psychiatry 50, 345–350 (2001).
65. Wells, G. B., Lopez, M. C. & Tanaka, J. C. The effects of ibogaine on dopamine
and serotonin transport in rat brain synaptosomes. Brain Res Bull. 48,
641–647 (1999).
66. Masson, G. R. et al. Recommendations for performing, interpreting and
reporting hydrogen deuterium exchange mass spectrometry (HDX-MS)
experiments. Nat. Methods 1–24, In Press.
Acknowledgements
This work was made possible through support from the Danish Council for Independent
Research (0602‐02740B to K.D.R., 0602-02100B and 4183-00581 to C.J.L.), the UCPH
bioSYNergy center of excellence and the Novo Nordic Foundation (NNF17OC0028582
to C.J.L.), and the Lundbeck Foundation (SGFR). The pEG BacMam vector was kindly
provided by Eric Gouaux, Ph.D., at the Vollum Institute. Thanks to Giuseppe Cazzamali,
Novo Nordisk Foundation Center for Protein Research, for kindly providing access to
facilities allowing SERT expression in HEK293expi cells. Rhizopuspepsin used for HDX-
MS as well as other proteases screened in this work were kindly provided by Petr Man at
BioCev, Czech Academy of Sciences.
Author contributions
K.D.R. and C.J.L. conceived and supervised the work. I.R.M. produced recombinant S.E.
R.T. with the help of M.S. and A.K.N. I.R.M. performed the H.D.X.-M.S. experiments. I.
R.M. and M.S. performed the S.P.A. experiments. I.R.M. and K.D.R. analyzed the H.D.X.-
M.S. data. C.J.L., K.D.R., S.G.F.R., and U.G. contributed with equipment, reagents, and
knowhow. I.R.M., C.J.L., and K.D.R. prepared the paper and all authors read and
commented it.
Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-
019-09675-z.
Competing interests: The authors declare no competing interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Journal peer review information Nature Communications thanks Argyris Politis and the
anonymous reviewers for their contribution to the peer review of this work. Peer reviewer
reports are available.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2019
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09675-z ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:1687 | https://doi.org/10.1038/s41467-019-09675-z | www.nature.com/naturecommunications 13
